Skip to main content
. 1999 Oct;48(4):564–572. doi: 10.1046/j.1365-2125.1999.00053.x

Table 2.

Pharmacokinetic parameters of tolterodine and active moiety (unbound tolterodine) at steady-state during 1 mg twice-daily administration of tolterodine l-tartrate for 2.5 days in the absence and presence of ketoconazole in subjects with deficient CYP2D6 activity.

graphic file with name bcp0048-0564-t2.jpg